Impel NeuroPharma Inc. (IMPL) Announces FDA Approval of TRUDHESA for Migraine
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Impel NeuroPharma Inc. (IMPL) Launches 3M Share Proposed Offering
September 7, 2021 4:01 PM EDTImpel NeuroPharma, Inc. (NASDAQ: IMPL) announced that it has commenced an underwritten public offering of 3,000,000 shares of its common stock. All of the shares of common stock are being offered by Impel. In addition, Impel intends to grant the underwriters a 30-day option to... More
Impel Neuropharma (IMPL) PT Raised to $55 at Cowen on FDA Approval
September 3, 2021 10:57 AM EDTCowen analyst Ken Cacciatore raised the price target on Impel Neuropharma (NASDAQ: IMPL) to $55.00 (from $35.00) while maintaining an Outperform rating.
The analyst commented, "The FDA has approved Trudhesa for the treatment of acute migraines with a clean label right in line with our... More
Impel NeuroPharma Inc. (IMPL) surges 59% as trading reumes on FDA approval
September 3, 2021 9:18 AM EDTImpel NeuroPharma Inc. (NASDAQ: IMPL) surges 59% as trading reumes on FDA approval
... More